Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-06-24T02:12:36.473Z Has data issue: false hasContentIssue false
  • English
  • Français

A Case Report: Improvement of Zuclopenthixol Decanoate Induced Tardive Dyskinesia After Switching to Paliperidone Palmitate.

Published online by Cambridge University Press:  15 April 2020

E. Yildizhan ,
F. Ozsoy  and
B. Ozata Yildizhan
E. Yildizhan
Affiliation:
Psychiatry, Niksar State Hospital, Tokat, Turkey
F. Ozsoy
Affiliation:
Psychiatry, Tokat Mental Hospital, Tokat, Turkey
B. Ozata Yildizhan
Affiliation:
Psychiatry, Erbaa State Hospital, Tokat, Turkey

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Long acting antipsychotics are an effective option in improving treatment adherence, but tardive dyskinesia can be problem in som cases1

Objectives

Atypical antipsychotics with long acting formulations offer a safer option for extrapyramidal side effects but it is not clear if they are safer in tardive dyskinesia.

Aims

We report a 45 year old male patient with 25 year history of schizophrenia aiming to reveal the effects of paliperidone palmitate on oropharyngeal dyskinesia.

Methods

Chlorpromazine, haloperidole, zuclopenthixol, olanzapine and quetiapine were the antipsychotics which were used in the last 12 months. The patient had been using olanzapine 20 mg/day, biperiden 4 mg/day and zuclopenthixol decanoate 200 mg every 2 weeks in the index consultation that the oropharyngeal dyskinesia was observed. Olanzapine was discontinued and since there was need for long acting antipsychotics because of the former history of treatment non-adherence, zuclopenthixol was switched to paliperidone palmitate 150 mg every 4 weeks. Abnormal Involuntary Movement Scale was used weekly to score the dyskinetic movements.

Results

Marked improvement in movement disorder was observed after a switch from zuclopenthixol decanoate to paliperidone palmitate.

Conclusion

Long acting atypical antipsychotics may be a preferable option in patients with tardive dyskinesia if treatment non-adherence is a problem.

Type
Article: 0904
Information
European Psychiatry , Volume 30 , Issue S1: Abstracts of the 23rd European Congress of Psychiatry , March 2015 , pp. 1
Copyright
Copyright © European Psychiatric Association 2015

References

Dolder, CRJeste, DVIncidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003; 53: 1142–114510.1016/S0006-3223(03)00170-7CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.